FibroGen Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>FibroGen Inc. filed its Q1 2024 10-Q, detailing financial performance and ongoing collaborations.</b>

AI Summary

FIBROGEN INC (KYNB) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. FibroGen Inc. filed a 10-Q report for the quarter ended March 31, 2024. The filing includes financial data and operational updates for the period. Key dates mentioned include 2024-03-31 for financial reporting and 2024-05-06 as the filing date. The company's business address is 409 Illinois Street, San Francisco, CA 94158. The report references agreements with Astellas, AstraZeneca, and Eluminex.

Why It Matters

For investors and stakeholders tracking FIBROGEN INC, this filing contains several important signals. This 10-Q provides investors with the latest financial snapshot and operational developments for FibroGen Inc. in early 2024. The filing highlights the company's continued engagement with key partners like Astellas and AstraZeneca, which are crucial for its drug development pipeline.

Risk Assessment

Risk Level: medium — FIBROGEN INC shows moderate risk based on this filing. The company's financial health and future prospects are tied to the success of its drug development programs and partnerships, which carry inherent risks of clinical trial failures and regulatory hurdles.

Analyst Insight

Monitor upcoming clinical trial results and partnership updates for FibroGen Inc. as they will significantly impact future revenue and stock performance.

Key Numbers

• 2024-03-31 — Reporting Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-05-06 — Filing Date (FILED AS OF DATE)
• 2834 — Standard Industrial Classification (STANDARD INDUSTRIAL CLASSIFICATION)
• 001-36740 — SEC File Number (SEC FILE NUMBER)

Key Players & Entities

• FIBROGEN INC (company) — FILER
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT
• 2024-05-06 (date) — FILED AS OF DATE
• 409 ILLINOIS STREET (address) — BUSINESS ADDRESS
• SAN FRANCISCO (city) — BUSINESS ADDRESS
• CA (state) — BUSINESS ADDRESS
• 94158 (zip_code) — BUSINESS ADDRESS
• Astellas (company) — fgen:AstellasMember

FAQ

Industry Context

FibroGen Inc. operates in the pharmaceutical preparations industry, focusing on the development of therapeutics.

Regulatory Implications

The company is subject to SEC regulations for public filings, including the quarterly 10-Q report.

What Investors Should Do

1. Analyze the detailed financial statements within the 10-Q for revenue, expenses, and cash flow.
2. Review any disclosed updates on clinical trials and regulatory submissions for FibroGen's drug candidates.
3. Examine the company's partnerships and licensing agreements for potential future revenue streams.

Key Dates

• 2024-03-31: Quarterly Period End — Financial reporting period for the 10-Q.
• 2024-05-06: Filing Date — Date the 10-Q was officially filed with the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from the previous year-end report.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20240331.htm (10-Q) — 2465KB
• fgen-ex10_1.htm (EX-10.1) — 25KB
• fgen-ex10_2.htm (EX-10.2) — 187KB
• fgen-ex10_3.htm (EX-10.3) — 33KB
• fgen-ex10_4.htm (EX-10.4) — 285KB
• fgen-ex31_1.htm (EX-31.1) — 9KB
• fgen-ex31_2.htm (EX-31.2) — 9KB
• fgen-ex32_1.htm (EX-32.1) — 8KB
• img88376381_0.jpg (GRAPHIC) — 5KB
• 0000950170-24-053554.txt (&nbsp;) — 10873KB
• fgen-20240331.xsd (EX-101.SCH) — 1710KB
• fgen-20240331_htm.xml (XML) — 1695KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 2 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 (Unaudited) 2 Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 (Unaudited) 4 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three Months Ended March 31, 2024 and 2023 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (Unaudited) 6 Notes to the Condensed Consolidated Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 42

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 80 Item 3. Defaults Upon Senior Securities 80 Item 4. Mine Safety Disclosures 80 Item 5. Other Information 80 Item 6. Exhibits 80

Signatures

Signatures 82 1 Table of Contents FIBROGEN, INC.

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 105,734 $ 113,688 Short-term investments 71,865 121,898 Accounts receivable, net ($ 7,122 and $ 6,079 from related parties) 37,083 12,553 Inventories 27,335 41,565 Prepaid expenses and other current assets 36,150 41,855 Total current assets 278,167 331,559 Restricted time deposits 1,658 1,658 Property and equipment, net 12,166 13,126 Equity method investment in unconsolidated variable interest entity 5,776 5,290 Operating lease right-of-use assets 64,751 68,093 Other assets 3,350 3,803 Total assets $ 365,868 $ 423,529 Liabilities, redeemable non-controlling interests and deficit Current liabilities: Accounts payable $ 4,353 $ 17,960 Accrued and other current liabilities ($ 45,870 and $ 39,814 to a related party) 164,286 172,891 Deferred revenue ($ 7,901 and $ 7,220 to related parties) 12,863 12,740 Operating lease liabilities, current 15,231 14,077 Total current liabilities 196,733 217,668 Product development obligations 17,446 17,763 Deferred revenue, net of current ($ 2,343 and $ 9,705 to a related party) 147,118 157,555 Operating lease liabilities, non-current 62,511 66,537 Senior secured term loan facilities, non-current 72,213 71,934 Liability related to sale of future revenues, non-current 52,216 51,413 Other long-term liabilities ($ 2,458 and $ 656 to a related party) 3,786 2,858 Total liabilities 552,023 585,728 Commitments and Contingencies Redeemable non-controlling interests 21,480 21,480 Stockholders' deficit: Preferred stock, $ 0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $ 0

View Full Filing

View this 10-Q filing on SEC EDGAR